Gemfibrozil inhibits CYP2c8-mediated cerivastatin metabolism in human liver microsomes

Drug Metabolism and Disposition

Volumn 30, Issue 12, 2002, Pages 1352-1356

  Wang, Jun Sheng ^a   Neuvonen, Mikko ^a   Wen, Xia ^a   Backman, Janne T ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DRUG METABOLITE; ERYTHROMYCIN; FURAFYLLINE; GEMFIBROZIL; KETOCONAZOLE; MEPHENYTOIN; PACLITAXEL; PYRIDINE; QUINIDINE; RECOMBINANT ENZYME; SULFAMETHOXAZOLE; SULFAPHENAZOLE; TESTOSTERONE; TRANYLCYPROMINE; TRIMETHOPRIM; TROLEANDOMYCIN; CYP2C8 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIDINE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROSOMES, LIVER; PYRIDINES;

EID: 0036892714     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.12.1352     Document Type: Article

References (28)

1. Backman JT, Kyrklund C, Kivistö KT, Wang JS, and Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122-129.
2. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther, in press.
3. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, and Radtke M (1997) Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25:321-331.
4. Boberg M, Angerbauer R, Kanhai WK, Karl W, Kern A, Radtke M, and Steinke W (1998) Biotransformation of cerivastatin in mice, rats and dogs in vivo. Drug Metab Dispos 26:640-652.
5. Charatan F (2001) Bayer decides to withdraw cholesterol lowering drug. BMJ 323:359.
6. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
7. Farmer JA (2001) Learning from the cerivastatin experience. Lancet 358:1383-1385.
8. Hargreaves MB, Jones BC, Smith DA and Gescher A (1994) Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metab Dispos 22:806-810.
9. Hiekman D, Wang JP, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
10. Hsu HC, Chen GL, Huang LC, and Hsu MY (1991) Validation of analytical methods: Gemfibrozil in human plasma using high performance liquid chromatography. Chung-Hua Yao Hsueh Tsa Chih 43:117-127.
11. Jemad M, Rao S, Salahudeen I, Chen BC, and Kates R (1999) Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatographyelectrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 736:19-41.
12. Kantola T, Kivistö KT, and Neuvonen PJ (1999) Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 54:851-855.
13. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, and Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340-345.
14. Mück W (1998a) Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 56 (Suppl 1):15-23.
15. Mück W, Ochmann K, Rohde G, Unger S, and Kuhlmann J (1998b) Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53:469-473.
16. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
17. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: An approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
18. Ong CE, Coulter S, Birkett DJ, Bhasker CR, and Miners JO (2000) The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 50:573-580.
19. Pogson GW, Kindred LH, and Carper BG (1999) Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 83:1146.
20. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA (2002a) Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512.
21. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, and Baillie TA (2002b) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051.
22. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247-3255.
23. Sallustio BC, Fairchild BA, and Pannall PR (1997) Interaction of human serum albumin with the electrophilic metabolite 1-0-gemfibrozil-beta-D-glucuronide. Drug Metab Dispos 25:55-60.
24. Staffa JA, Chang J, and Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540.
25. Taavitsainen P, Juvonen R, and Pelkonen O (2001) In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine) and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29:217-222.
26. Wang JS, Wen X, Backman JT, and Neuvonen PJ (2002) Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. J Pharmacol Exp Ther 302:43-49.
27. Wen X, Wang JS, Backman JT, Kivistö KT, and Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359-1361.
28. Wen X, Wang JS, Backman JT, Laitila J, and Neuvonen PJ (2002) Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 30:631-635.